View Older Stories View More Recent Stories

Oct 29, 2019 08:00AM Generation Bio Welcomes Steven Dowdy, Ph.D., to its Scientific Advisory Board
Oct 29, 2019 07:00AM CAMP4 Therapeutics Expands Board of Directors With Appointment of Steven Holtzman as Chair and Dr. Paula Ragan as Director
Oct 29, 2019 07:00AM Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Oct 22, 2019 12:00PM Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
Oct 21, 2019 08:00AM Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
Oct 17, 2019 08:00AM Cadent Therapeutics Appoints Christopher Kenney, M.D. as Chief Medical Officer and Provides Clinical Update
Oct 14, 2019 07:00AM Cadent Therapeutics to Present at the 5th Annual BMO Private Company Showcase
Oct 7, 2019 06:00AM Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing
Oct 1, 2019 06:30AM Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
Sep 11, 2019 08:00AM Disarm Therapeutics Presents Data at ECTRIMS 2019 Supporting SARM1 as a Novel Therapeutic Target for Multiple Sclerosis
Sep 5, 2019 07:00AM IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due
Sep 4, 2019 08:00AM Disarm Therapeutics Announces First Subject Enrolled in EPIPHANY Natural History Study of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Aug 28, 2019 07:00AM Cadent Therapeutics to Present at Upcoming Investor Conferences
Aug 23, 2019 08:00AM Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
Aug 21, 2019 07:00AM Cadent Therapeutics Appoints John McBride as Chief Financial Officer and Expands its Leadership Team
Aug 19, 2019 08:00AM Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein
Aug 6, 2019 02:12PM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 6, 2019 02:11PM Form 13F-NT ATLAS VENTURE FUND VI For: Jun 30
Aug 6, 2019 02:11PM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 6, 2019 02:10PM Form 13F-HR Atlas Venture Associates For: Jun 30
Aug 6, 2019 02:10PM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 30, 2019 05:26PM Form SC 13D AVROBIO, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 29, 2019 09:13PM Form 4/A AVROBIO, Inc. For: Jul 19 Filed by: Atlas Venture Fund X, L.P.
Jul 29, 2019 09:12PM Form 3 AVROBIO, Inc. For: Jul 19 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 25, 2019 07:30AM Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
Jul 23, 2019 04:10PM Form 4 AVROBIO, Inc. For: Jul 19 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jul 22, 2019 08:00AM Disarm Therapeutics Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer
Jul 15, 2019 08:00AM Kymera Therapeutics Announces Leadership Transitions
Jun 28, 2019 08:30AM Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
Jun 25, 2019 06:06PM Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 25, 2019 08:00AM Generation Bio Appoints Katherine Fitzgerald, Ph.D., to its Scientific Advisory Board
Jun 19, 2019 06:32PM Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 6, 2019 01:26PM Harvard Business School Announces $10 Million Gift Renewal from the Blavatnik Family Foundation and Introduces 2019-2020 Blavatnik Fellows in Life Science Entrepreneurship
May 31, 2019 08:00AM Generation Bio to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 07:00AM Cadent Therapeutics Announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
May 28, 2019 07:00AM Cadent Therapeutics to Present at the Jefferies Healthcare Conference
May 23, 2019 07:00AM Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression
May 13, 2019 05:28PM Form 13F-NT ATLAS VENTURE FUND VI For: Mar 31
May 13, 2019 04:10PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 04:09PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 03:48PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 13, 2019 01:44PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 8, 2019 07:00AM IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
May 7, 2019 08:00AM Kyn Therapeutics Strengthens Leadership Team with Key Appointments
May 7, 2019 08:00AM Science2Startup Symposium Convened Close to 300 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections to Advance Scientific Innovation and Entre
Apr 18, 2019 08:00AM Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
Apr 18, 2019 07:00AM Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
Apr 12, 2019 07:00AM Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
Apr 3, 2019 06:30AM Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Apr 1, 2019 05:00AM Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million
View More Recent Stories View Older Stories